Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia

Close metadata

OBJECTIVE

To study the efficacy and safety of the drug Picamilon with various therapy regimens in patients with stage II chronic cerebral ischemia (CCI).

MATERIAL AND METHODS

An open cohort clinical study involved 50 patients diagnosed with stage II CCI aged 51 to 69 years (average age 62.2±8.98 years). Patients received Picamilon first parenterally 200 mg (100 mg/ml, 2 ml) intravenously for 10 days, then orally in 50 mg tablets 3 times a day for 60 days. The total duration of therapy in the group was 70 days. The study included 3 visits (before treatment, after completion of the course, 1.5 months after completion of treatment). The dynamics of cognitive status according to the Montreal Cognitive Assessment Scale, vegetative disorders according to the A.M. Vane scale, neurological disorders according to the A.I. Fedin scale, and sleep quality according to the Ya. I. Levin scale were compared. The state of cerebral blood flow and endothelium was studied before and after treatment: dopplerography of cranial vessels, assessment of the level of methylated forms of arginine (ADMA, MMA, SDMA) and their ratios. The registration of adverse events against the background of therapy and the tolerability of treatment by patients was also carried out.

RESULTS

Against the background of Picamilon treatment, a significant positive dynamics of the MoCA scale results was observed in the general sample of patients, increasing in the delayed period (20.9, 24.6 and 25.9, p<0.0001 and p=0.0006); sleep normalization was observed in 55% of patients by Visit 2 and in 81% of patients by Visit 3 (p<0.0001 and p=0.0025). Improvement of neurological functions is noted in 84% of patients, the score on the Fedin A.I. scale significantly decreases after treatment from 17.4±9.34 to 8.06±6.84 (p<0.0001) and to 5.31±5.71 in the delayed period (p=0.0002). Normalization of vegetative status was observed in 38% of patients with stage II CCI, and in 60% of cases there was a decrease in the severity of vegetative dystonia syndrome (p=0.0001). Picamilon therapy has high efficacy in assessing clinical outcomes (100%), good tolerability in 98% of patients and is characterized by a favorable safety profile (in 92% of patients). Picamilon significantly affects the parameters of cerebral hemodynamics: increases the linear velocity of blood flow, reduces the thickness of the intima-media complex and the resistance index. It affects markers of NO metabolism and endothelial function: significantly reduces elevated levels of ADMA and ADMA/MMA and (ADMA+SDMA)/MMA ratios.

CONCLUSION

The use of Picamilon is effective in patients with stage II CCI in the form of step therapy contributes to a significant regression of neurological deficit, cognitive impairment, improvement of sleep quality and autonomic function; improves vascular endothelial function, reduces the risk of cardiovascular complications. Picamilon is a pathogenetic therapy agent that prevents the progression of CCI.

Keywords:

chronic cerebral ischemia

cognitive impairment

moderate cognitive impairment

cerebrovascular diseases

neurometabolic therapy

Picamilon

endothelial function

Authors:

Danilov A.B.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-8904-2538

Shindryaeva N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-6560-2756

Borodulina I.V.

Russian Medical Academy of Continuing Postgraduate Education

SPIN RSCI: 2152-5737
ORCID: 0000-0001-7526-1553

Lunegov T.D.

Khromsistemslab LLC

ORCID: 0000-0002-7020-9446

Kristeleva D.A.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

07.08.2024

Accepted:

21.08.2024

List of references:

Shakhparonova NV, Kadykov AS. Chronic vascular diseases of the brain: an algorithm for diagnosis and treatment. Consilium Medicum. 2017;19(2):104-109. (In Russ.).
Zaharov VV, Vahnina NV, Gromova DO, Tarapovskaya AV. Chronic cerebral circulatory insufficiency: a description of the clinical case. Terapevticheskij Arhiv. 2016;88(4):93-99. (In Russ.).
Kulesh AA, Emelin AY, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
Artem’ev DV, Zaharov VV, Levin OS, et al. Aging and neurodegenerative disorders: cognitive and motor disorders in old age. Ed. Yahno NN. M.: Servier. 2005. (In Russ.).
Vy`govskaya SN, Nuvakhova MB, Doroginina AYu, Rachin AP. Chronic cerebral ischemia — from correct diagnosis to adequate therapy. RMJ. 2015;12:694-700. (In Russ.).
Veriugina NI, Chimagomedova ASh, Starovoitova IM, Levin OS. Endothelial dysfunction in chronic vascular encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro20171176273-80
Levin OS. Dyscirculatory encephalopathy: from pathogenesis to treatment. Trudnyj Pacient. 2010;4(8):3-12. (In Russ.).
Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertension Research. 2012;35:1039-1047. https://doi.org/10.1038/hr.2012.138
Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000;123:1784-1812.
Fateeva V, Vorob’eva OV. The correlation between endothelial dysfunction and depressive disorder in middle-aged patients with hypertension-associated microangiopathy. 4th European Stroke Organisation Conference. (Gothenburg, Sweden 2018). AS23-028.
Markin SP. A modern approach to the diagnosis and treatment of chronic cerebral ischemia. RMJ. 2010;8:445. (In Russ.).
Antipenko EA, Gustov AV. Chronic cerebral ischemia the current state of the problem. Medical Advice. 2016;19:38-43. (In Russ.).
Bogolepova AN. Vascular depression and cognitive dysfunction. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2019;11(Suppl. 3):26-31. (In Russ.). https://doi.org/10.14412/2074-2711-2019-3S-26-31
Damulin NV. Dyscirculatory encephalopathy: pathogenesis, clinic, treatment: Guidelines. M. 2005. (In Russ.).
Levin OS. Dyscirculatory encephalopathy: modern ideas about the mechanisms of development and treatment. Consilium Medicum. 2006;8:2-7. (In Russ.).
Zakharov VV, Sleptsova KB, Martynova OO. Chronic cerebral ischemia: a view from the XXI century. RMJ. 2021;5:45-49. (In Russ.).
Zakharov VV, Borodulina IV, Vakhnina NV. Treatment of patients with chronic cerebral ischemia: experience of using the combined neuroprotective drug Picamilon Ginkgo. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):95-103. (In Russ.). https://doi.org/10.17116/jnevro202212209195
Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
Suslina ZA, Geraskina LA, Fonyakin AV. Arterial hypertension, vascular pathology of the brain and antihypertensive treatment. M.: ZAO «Mediagafiks». 2006. (In Russ.).
SHtok VN. Pharmacotherapy in Neurology: A Practical Guide. 4th ed. M.: MNA. 2006. (In Russ.).
Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinic, treatment). M.: MED-press. 2018. (In Russ.).
Clinical guidelines «Ischemic stroke and transient ischemic attack in adults». Ministry of Health of the Russian Federation. 2024. (In Russ.).
Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD. Integrative assessment of the effectiveness and safety of outpatient use of Picamilon. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):119-130. (In Russ.). https://doi.org/10.17116/jnevro2024124071119
Gan’shina TS, Kurdyumov IN, Maslennikov DV. The effectiveness of picamilon in combined vascular pathology of the brain and heart. Eksperimental’naya i Klinicheskaya Farmakologiya. 2022;85(1):3-6. (In Russ.).
Latysheva VYa, Galinovskaya NV, Shaporova OV, et al. Treatment of patients with dyscirculatory encephalopathy. Recept. 2008;3(59):69-75. (In Russ.).
Saharov VYu, Skripnik YuV. The use of picamilon in restorative treatment in post-stroke patients with emotional and cognitive impairments. Davidenkov readings. Conference materials. St. Peterburg. «Chelovek i ego zdorov’e». 2021;309-310. (In Russ.).
Kostenko EV, Kashezhev AG, Petrova LV, Eneeva MA. Medical support of rehabilitation of stroke patients: the role of GABA-ergic drugs. Meditsinskiy Sovet. 2023;17(21):8-19. (In Russ.). https://doi.org/10.21518/ms2023-408
Lihodeeva VA, Spasov AA, Isupov IB, Mandrikov VB. The effect of picamilon on the parameters of cerebral blood flow in maladapted swimmers with different types of systemic hemodynamics. Vestnik Novyh Medicinskih Tekhnologij. 2011;18(1):150-153. (In Russ.).
Ershov IN, Luchkina EV, Pokrovskij MV, Pokrovskaya TG. Investigation of endothelio- and cardioprotective effects of lamotrigine, picamilon and valproates in experimental endothelial dysfunction. Kubanskij Nauchnyj Medicinskij Vestnik. 2009;3(108):50-53. (In Russ.).
Handbook on the formulation of the clinical diagnosis of diseases of the nervous system. Ed. VN Shtok, OS Levin. M.: MNA, 2006. (In Russ.).
Nasreddine ZS, Phillips NA, Bédirian V. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Ger Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Vejn AM. Vegetative disorders. Clinic, treatment, diagnosis. Guide. M.: MIA, 2010. (In Russ.).
Levin YaI, Eligulashvili TS, Posohov SI, et al. Pharmacotherapy of insomnia: the role of Imovan. Sleep disorders. Ed. YuA Aleksandrovskiy, AM Vejn. SPb.: Medicinskoe informacionnoe agentstvo. 1995;56-61. (In Russ.).
Fedin AI. Diagnosis and treatment of chronic cerebral ischemia. Consilium Medicum. 2016;18(2):8-12. (In Russ.).
Rodionov RN, Blokhin IO, Galagudza MM, et al. The emerging role of asymmetric dimethylarginine in cardiovascular disease. Arterial’naya Gipertenziya. 2008;14(4):306-314. (In Russ.). https://doi.org/10.18705/1607-419X-2008-14-4-306-314
Baum C, Johannsen SS, Zeller T, et al.; Gutenberg Health Study investigators. ADMA and arginine derivatives in relation to non-invasive vascular function in the general population. Atherosclerosis. 2016;244:149-156. https://doi.org/10.1016/j.atherosclerosis.2015.10.101
Bahls M, Friedrich N, Atzler D, et al. L-Arginine and SDMA Serum Concentrations Are Associated with Subclinical Atherosclerosis in the Study of Health in Pomerania (SHIP). PLoS One. 2015;10(6):e0131293. https://doi.org/10.1371/journal.pone.0131293
Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833. https://doi.org/10.1161/JAHA.115.001833
Perfilova VN, Borodkina LE. The participation of the gamma-aminobutyric acid-ergic system in the regulation of cerebral circulation. Vestnik Rossijskoj Voenno-Medicinskoj Akademii. 2014;1(45):203-211. (In Russ.).

Close metadata